Modulation of PTEN expression via oligomeric compounds
OwnerBrett P. Monia, C. Frank Bennett +2inventors
InventorsBrett P. Monia, C. Frank Bennett, Brenda F. Baker, Timothy Vickers
Life of this patent
Estimating the term…
Loading patent…
OwnerBrett P. Monia, C. Frank Bennett +2inventors
InventorsBrett P. Monia, C. Frank Bennett, Brenda F. Baker, Timothy Vickers
Estimating the term…
Oligomeric compounds, compositions and methods are provided for modulating the expression of PTEN. The compositions comprise oligomeric compounds, particularly double stranded oligomeric compounds, targeted to nucleic acids encoding PTEN. Methods of using these compounds for modulation of PTEN expression and for treatment of diseases and conditions associated with expression of PTEN are provided. Such conditions include diabetes and hyperproliferative conditions. Methods for decreasing blood glucose levels, inhibiting PEPCK expression, decreasing blood insulin levels, decreasing insulin resistance, increasing insulin sensitivity, decreasing blood triglyceride levels or decreasing blood cholesterol levels in an animal, among others, using the compounds of the invention are also provided. The animal is preferably a human; also preferably the animal is a diabetic animal.
A double stranded oligomeric compound comprising 8-50 nucleobases, said double stranded oligomeric compound hybridizable under stringent hybridization conditions to a nucleic acid molecule encoding PTEN.
A double stranded oligomeric compound which hybridizes to one or more active sites on a nucleic acid molecule encoding PTEN.
A method of selecting a double stranded oligomeric compound comprising the steps of;
A method of identifying one or more target regions on a target RNA comprising the steps of;
A method of identifying double stranded oligomeric compounds, said method comprising the steps of;
A method for identifying an optimized expression modulator of PTEN RNA comprising the steps of:
A double stranded oligomeric compound, 8-50 nucleobases in length, targeted to a PTEN RNA, wherein said double stranded compound has a least 70% sequence homology to a complement of said PTEN RNA.
Dependencies are inferred from the claim text.